% change of SUVmean (% SUVmean)= (SUVinitial-SUVfollow-up)/SUVinitial X 100 After lesion-based analysis, we performed patient-based analysis. The patient-based analysis was conducted by using the mean values of SUVmax and SUVmean of all affected spines and adjacent soft tissues of individual patients.
Results:
Patients Characteristics. Overall, 30 patients (11 men, 19 women with 89 lesions were assessed on F-18 FDG PET/CT. 31 lesions in 11 patients were TSI, and 58 lesions in 19 patients were PSI. Residual diseases were found in 14 lesions of 4 patients. Among them, 4 lesions in 1 patient were TSI. The mean follow-up period was 423.8±258.8 days (range, 110~962 days; median, 370 days).
Comparison of quantitative indices of F-18 FDG PET/CT between residual and non-residual spine infection. The SUVmax were significantly declined after treatment in both of residual (2.85±1.17 vs 2.06±1.03; p<0.0001) and non-residual SI (4.31±2.07 vs 1.44±0.46; p<0.0001). The SUVmean were also decreased after treatment in both of residual (1.45±0.45 vs 1.04±0.29; p=0.0014) and non-residual SI (2.09±1.03 vs 0.81±0.25; p<0.0001). The SUVmax were not significantly changed after treatment in residual SI (2.79±1.26 vs 2.06±1.04; p=0.125). However, non-residual SI (4.24±1.9 vs 1.53±0.47; p<0.0001) showed statistically significant decline in SUVmax after treatment. Also, the SUVmean were not significantly changed after treatment in residual SI (1.4±0.44 vs 1.02±0.32; p=0.125). However, nonresidual SI (2.03±0.87 vs 0.83±0.19; p<0.0001) showed statistically significant decline in SUVmean after treatment. The residual SI demonstrates significant lower values of % SUVmax and % SUVmean than those of non-residual SI by both of lesion-based analysis (% SUVmax : 28.4±18 % vs 59.5±19.6 %, p<0.0001; % SUVmean : 25.7±17.9 % vs 53.2±21.8 %, p=0.0001) and patient-based analysis (% SUVmax : 25±19.2 % vs 57.8±18.4 %, p=0.0104; % SUVmean : 24.7±15.8 % vs 53.4±15.8 %, p=0.0073) Prediction of residual disease by lesion-based analysis. Receiver operating curve (ROC) analyses were performed to determine optimal cut-off values of % SUVmax and % SUVmean for the differentiation of residual and nonresidual SI after treatment. When 43.01 % of % SUVmax was used as threshold value for differentiation of residual and non-residual disease, the area under curve (AUC) was 0.879 (standard error, 0.0391; 95% CI, 0.793-0.938, p=0.0001). The sensitivity and specificity were 85.7 %, 82.6 %, respectively. The positive and negative predictive values were 48 %, 96.9 %, respectively. Prediction of residual disease by patient-based analysis. ROC analyses were also performed to determine optimal cut-off values of % SUVmax and % SUVmean for the differentiation of residual and non-residual SI after treatment by patient-based analysis. When 46.14 % of % SUVmax was used as threshold value for differentiation of residual and non-residual disease, AUC was 0.904 (standard error, 0.0621; 95% CI, 0.739-0.979, p=0.0001). The sensitivity and specificity were 100 %, 76.9 %, respectively. The positive and negative predictive values were 40 %, 100 %, respectively. Residual disease free survival after treatment. Survival analysis was conducted by Kaplan-Meier and Cox proportional hazard model by patientbased analysis to define potent predictors of residual disease after treatment of SI. The Kaplan-Meier analysis illustrates the significant relationships between the % SUVmax and % SUVmean and residual disease free survival (% SUVmax, log rank statistic, 5.69; p=0.017: % SUVmean, log rank statistic, 11.24; p=0.0036). The Cox proportional hazard model using multivariate analysis for forward selection identified % SUVmax as an independent prognostic factor for residual SI after treatment.
CONCLUSION:
F-18 FDG PET/CT is useful for discrimination of residual and non-residual SI after treatment. Among the various quantitative indices, % SUVmax is a potent predictor of residual SI in the current study. However, these findings should be validated by large population based study.
